Clinical Trials Logo

Prostate Cancer Stage IV clinical trials

View clinical trials related to Prostate Cancer Stage IV.

Filter by:
  • None
  • Page 1

NCT ID: NCT05655715 Recruiting - Clinical trials for Metastatic Castration-resistant Prostate Cancer

Checkpoint Inhibitors and SBRT for mCRPC

CheckPRO
Start date: November 25, 2019
Phase: Phase 2
Study type: Interventional

The goal of this investigator-initiated, single-center, and randomized phase II trial is to investigate the potential synergistic effect of combining stereotactic body radiotherapy of a single soft tissue- or bone metastasis with ipilimumab and nivolumab in patients with mCRPC and perform translational analyses on tissue and blood, searching for predictive biomarkers of efficacy and toxicity. Participants will be randomized to receive ipilimumab and nivolumab with or without stereotactic body radiotherapy (SBRT).

NCT ID: NCT03432780 Active, not recruiting - Clinical trials for Prostate Cancer Stage IV

Radiation-hormone and Docetaxel VS Radiation-hormone in Patients With High-Risk Localized Prostate Cancer

QRT-SOGUG
Start date: December 18, 2008
Phase: Phase 2
Study type: Interventional

A prospective, multicenter, parallel-group, open-label, randomized, phase II Clinical Study of Radiation Therapy, Hormone Therapy and Docetaxel Versus Radiation Therapy and Hormone Therapy in Patients with High-Risk Localized Prostate Cancer (Stage III and IV) whose primary objective is determine the percentage of patients free of biochemical recurrence within 5 years of receiving a combination of radiation therapy with docetaxel associated with hormone therapy or the standard of care of radiation therapy and hormone therapy in patients with stage III and IV localized prostate cancer with a poor prognosis.